Skip to main navigation

Our Company
Our Assets
- Overview
- Publications & Presentations
Our Commitment
Investors & Media

Investors & Media

We are driven to develop meaningful therapies for patients while creating value for stockholders.

Investors & Media

Corporate Profile

We are a biopharmaceutical company on a mission to develop treatments for serious diseases.

Press Releases

Dec 04, 2023

Cyclerion Appoints Regina Graul, Ph.D., as President

Nov 30, 2023

Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator

Jul 31, 2023

Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets

Jun 01, 2023

Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement

Stock Quote

Change

Volume

52 Week High

52 Week Low

Apr 18, 2024 4:09 PM EDT

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Print Page Email Alerts RSS Feeds

© 2024 Cyclerion Therapeutics, Inc. All Rights Reserved.

Privacy Policy. Terms of Use. Contact.

Top